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The importance of epigenetic modifications such as DNA methylation in tumorigenesis is increasingly being appreciated. To
define the genome-wide pattern of DNA methylation in pancreatic ductal adenocarcinomas (PDAC), we captured the methyla-
tion profiles of 167 untreated resected PDACs and compared them to a panel of 29 adjacent nontransformed pancreata using
high-density arrays. A total of 11,634 CpG sites associated with 3,522 genes were significantly differentially methylated (DM)
in PDAC and were capable of segregating PDAC from non-malignant pancreas, regardless of tumor cellularity. As expected,
PDAC hypermethylation was most prevalent in the 50 region of genes (including the proximal promoter, 50UTR and CpG
islands). Approximately 33% DM genes showed significant inverse correlation with mRNA expression levels. Pathway analysis
revealed an enrichment of aberrantly methylated genes involved in key molecular mechanisms important to PDAC: TGF-b, WNT,
integrin signaling, cell adhesion, stellate cell activation and axon guidance. Given the recent discovery that SLIT-ROBO muta-
tions play a clinically important role in PDAC, the role of epigenetic perturbation of axon guidance was pursued in more detail.
Bisulfite amplicon deep sequencing and qRT-PCR expression analyses confirmed recurrent perturbation of axon guidance path-
way genes SLIT2, SLIT3, ROBO1, ROBO3, ITGA2 and MET and suggests epigenetic suppression of SLIT-ROBO signaling and up-
regulation of MET and ITGA2 expression. Hypomethylation of MET and ITGA2 correlated with high gene expression, which was
associated with poor survival. These data suggest that aberrant methylation plays an important role in pancreatic carcinogene-
sis affecting core signaling pathways with potential implications for the disease pathophysiology and therapy.
Pancreatic ductal adenocarcinoma (PDAC), the predominant
form of pancreatic cancer is usually diagnosed at an
advanced stage. Optimal treatment involves surgery with
adjuvant chemotherapy, however <20% of patients are suita-
ble for operative resection as the majority has either locally
advanced or metastatic disease at diagnosis.1,2 Therapy for
advanced disease is largely ineffective and the 5-year survival
remains <5%. Consequently, novel therapeutic and early
detection strategies are urgently needed.
DNA methylation mostly occurs at cytosine residues in
the context of CG dinucleotides (CpG sites) present across
the genome, regions rich in these CpG sites are termed CpG
islands.3 Altered DNA methylation is implicated in tumor
initiation and progression for several cancer types4,5 with
hypermethylation of CpG islands and promoter regions asso-
ciated with transcriptional silencing of tumor suppressor
genes.6 Conversely, hypomethylation is associated with over-
expression of oncogenes6 and genomic instability,7 although
the mechanisms are yet to be completely understood.
It is well established that tumors arise through the accu-
mulation of genetic and epigenetic aberrations; the patterns
of which differ from cancer to cancer. While recent PDAC
exome sequencing studies8–10 have made signiﬁcant inroads
into identifying the common somatic point mutations and
copy number alterations, genome-wide patterns of DNA
methylation in PDAC are yet to be fully characterized. To
date, DNA methylation has been limited to small number of
CpG sites (1,500–244,000) in PDAC xenografts (n 5 30) or
cell lines (n 5 9214).11–13 While these studies suggest that
DNA methylation is important in the development and pro-
gression of PDAC, further characterization within larger
cohorts is needed to determine the scale and the contribution
of methylation to molecular mechanisms driving this hetero-
geneous and complex disease.
This study reports a large scale methylation and expres-
sion proﬁling of a cohort of 167 PDAC and compared them
to 29 adjacent nonmalignant pancreas using Inﬁnium 450k
methylation arrays (Illumina). We show that aberrant DNA
methylation is widespread in pancreatic cancer and is
enriched in many of the core cancer-signaling pathways
known to be important in pancreatic carcinogenesis. Of par-
ticularly, interest was the recurrent hypermethylation/reduced
expression of SLIT-ROBO genes, which are key components
of axon guidance signaling, a pathway recently implicated in
this disease.10 Furthermore hypomethylation/increased
expression of MET and ITGA2 was found to be associated
with poor patient survival. Taken together, these data support
an orchestrated deregulation of DNA methylation contribut-
ing to pancreatic carcinogenesis and an increasing impor-
tance of SLIT-ROBO/axon guidance signaling in PDAC.
Material and Methods
Patients and sample collection
Samples from 167 tumors and 29 adjacent nonmalignant
pancreatic tissues were collected from nontreated PDAC
patients who underwent resection surgery. Patients were
recruited preoperatively and consented using ICGC ethical
What’s new?
Based on a large genome-wide scan of DNA methylation, this study reports that global DNA methylation patterns can robustly
segregate tumor and non-malignant pancreata. Cancer methylation also affects key pathways in pancreatic carcinogenesis,
including TGF-b, WNT, and axon guidance signaling. This study confirms that methylation plays an important role in the devel-
opment and progression of pancreatic cancer, with implications for both ongoing research and therapeutic development.
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and approved process (Project Number: 2009000745). Frozen
sections of the tested samples underwent histological evalua-
tion for tumor and non-neoplastic tissue conformation and
tumor content estimation. Samples were collected as part of
the Australian Pancreatic Cancer Genome Initiative.
Genomic DNA isolation, bisulfite conversion and 450 K
methylation arrays
DNA was extracted from fresh frozen tissues using the All-
Prep DNA/RNA Mini Kit (Qiagen). Genomic DNA (500 ng)
was bisulﬁte converted using the EZ DNA methylation Kit
(Zimo Research) following the manufacturer’s protocol with
modiﬁcation for Illumina Methyaltion arrays. Bisulﬁte con-
verted DNA was whole genome ampliﬁed and hybridized to
Inﬁnium Human Methylation 450K BeadChips (Illumina)
according to the manufacturer’s protocol. Arrays were
scanned using an iScan (Illumina). Cellularity of each tumor
sample was estimated using SNP array data (Omini1-Quad,
V1 and Omini2.5-8,V1.0– Illumina) and qPure tool14 (Sup-
porting Information Table S1).
Data preprocessing and initial quality assessment
The GenomeStudio v 2011.1 (Illumina) with methylation
module (v 1.6.1), was used to process the raw image data.
The assay performance was assessed using the “Control
Dashboard” in GenomeStudio. Overall sample quality was
determined through total number of detected CpGs and the
distribution of average beta values for all CpGs. One sample
was excluded in this study, as it did not pass these basic
quality assessments.
The reproducibility of the data was measured by sample
replication across different batches of bisulﬁte conversion,
with a correlation coefﬁcients > 0.99 across replicated sam-
ples. Examples of the correlation between replicates are pre-
sented in the Supporting Information Figure S1. Supporting
Information Figures S2 and S3 show PCA analysis of all 196
samples colored by batch and by cellularity, respectively. No
obvious batch effect was observed, main separation is due to
the sample type and cellularity (Supporting Information Fig.
S3). The methylation array data have been deposited into the
Gene Expression Omnibus (Accession number –GSE49149).
Data analysis of 450K methylation arrays
IDAT ﬁles were analyzed using the minﬁ package and
subset-quantile within-array normalization (SWAN).15 Probes
on chromosomes X and Y, probes with detection p-value
>0.01 in one or more samples and probes with SNP in the
10 last bases or with two or more SNPs in the probe
sequence were excluded from analysis. The differential meth-
ylation (DM) analysis was performed using 402,496 autoso-
mal CpGs using the “dmpFinder” minﬁ function. Probes
were considered DM if p-value corrected by the Benjamini
and Hochberg method was <0.001 and the Db (the average
beta value in PDAC samples minus the average beta value in
nonmalignant samples) was  0.2. The Wilcoxon rank sum
test was used to compare levels of methylation in speciﬁc
regions of the genome between PDAC and nonmalignant
samples.
Clustering analysis
For hierarchical clustering the R function “hclust” with
Euclidean distance and complete linkage clustering method
was used in combination with “heatmap3” function. The
principle component analysis (PCA) and plots were gener-
ated using the “pca” function of the R package mixOmics
version 4.0-2, (previously named integrOmics,16 with param-
eters “center” and “scale” set true).
The recursively partitioned mixture model (RPMM) was
used to identify tumor subtypes. The FANNY algorithm was
used for initialization and level-weighted of Bayesian infor-
mation for the split criterion as implemented in the RPMM
R package17 using the 2786 probes most variable (SD  0.17)
across all tumors (n 5 167).
Pathway analysis
To determine potential biological relevance of CpG sites DM
in PDAC pathway analyses were performed using the Inge-
nuity Pathway Analysis software (Ingenuity Systems; http://
www.ingenuity.com) and MetaCore package (Thomson
Reuters).
Validation by amplicon deep-sequencing
A subset of 96 PDAC and 15 nontumor samples were used
to validate the array data by amplicon deep-sequencing using
Ion-Torrent (Life Technologies) or MiSeq (Illumina)
sequencers. Primers were design using the MethPrimer18 pro-
gram to amplify regions containing CpG sites DM in genes
from SLIT-ROBO pathway, ITGA2, MET and genes involved
in stellate cell activation TNF, COX2, EGFR and TGFBR1.
Primers and amplicon size are presented in the Supporting
Information Table S2. Amplicons were pooled and sequenced
on Ion Torrent using the 318 chip and 200 bp chemistry or
on MiSeq with the Nextera kit. The Ion Torrent data was
mapped using TMAP (Life Technologies) and MiSeq data
was mapped using BWA backtrack v0.7.5a. For each potential
methylated base being interrogated in the amplicon the num-
bers of reads with methylated cytosines were counted. Per-
centage of methylation was calculated by (number of reads
with methylated C/total reads) 3 100.
Gene expression profiling
RNA from 121 PDAC and 8 nontumor samples was
extracted using the AllPrepDNA/RNA Mini Kit (Qiagen).
Total RNA (150 ng) was ampliﬁed and labeled using the Illu-
mina TotalPrep RNA Ampliﬁcation Kit (LifeTechnologies).
Ampliﬁed RNA (750 ng) was hybridized to Illumina human
HT12 (V4) arrays following manufacturer’s protocol and
scanned on Bead Array Reader or iScan (Illumina). The
intensities were extracted using the GenomeStudio software
(Illumina). Data was background corrected, log2-transformed
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and quantile normalized as implemented in the Lumi pack-
age.19 The gene expression array data have been deposited
into the Gene Expression Omnibus (Accession number –
GSE36924).
RT-PCR analysis used TaqMan probes for target genes
(Life Technologies). cDNA was synthesized using 500 ng of
total RNA, random primers and SuperScript III (Life Tech-
nologies). Relative gene expression quantiﬁcation was per-
formed using the ViiA 7 Real Time PCR System V1.2 (Life
Technologies) and the DDCT method.
Correlation methylation-gene expression
The relationship between methylation probes and gene
expression probes was obtained in the GenomeStudio Meth-
ylation module using the vendor lookup table. Spearman cor-
relations were calculated and the p-values were corrected for
false discovery rate resulting in q-values using the R package
fdrtool.20 The correlation was considered signiﬁcant when q-
value < 0.05.
Results
Defining a robust methylation signature for PDAC
The clinical features for the cohort (n 5 167 PDAC) are
summarized in Supporting Information Table S3. Tumor
content (cellularity) averaged 44%, ranging from 12 to 97%
based on high-density SNP arrays and qPURE analysis14
(Supporting Information Table S1). The distribution of tumor
cellularity was characteristic of primary PDACs, which is
typiﬁed by the presence of an extensive desmoplastic stroma.
Sample cellularity is known to affect sensitivity of detecting
DM sites, and to assess the inﬂuence of cellularity on our
ability to detect DM sites, two analyses were carried out: (i)
tumors with  70% cellularity (n 5 31) vs. adjacent nonma-
lignant pancreas (n 5 29) and (ii) tumors with  20% cellu-
larity (n 5 140) vs. adjacent nonmalignant pancreas (n 5
29). A total of 78,162 CpG sites (19.42% of total CpG sites)
and 105,516 (26.22% of total CpG sites) showed signiﬁcant
DM in tumors with  70 and  20% cellularity, respectively
(adjusted p-value < 0.001). Surprisingly, 86% of the DM
probes in the high cellularity cohort were also seen in the
cohort with cellularity  20% suggesting that PDAC pos-
sesses a robust set of methylation changes that were not con-
founded by cellularity (Supporting Information Fig. S4). To
ensure that the most robust set of DM probes in PDAC was
used for further analyses, an additional threshold was applied
to DM probes (Db  0.2, where Db 5 the average beta value
of PDAC samples minus the average beta value of adjacent
nonmalignant pancreas). This approach identiﬁed 11,634 DM
methylated probes (Supporting Information Table S4), with
adjusted p-value <0.001 and Db  0.2 in PDAC samples
with 20% or greater tumor cellularity.
This robust set of PDAC DM CpG sites (n 5 11,364) was
not randomly distributed across the genome. The majority of
the 5,203 signiﬁcantly hypomethylated sites were located in
gene bodies (58%) and outside CpG islands (88%; Fig. 1a).
From the 6,431 PDAC hypermethylated sites, 81% were
located in CpG islands and 65% located in promoter regions
(CpG sites located within 1,500 bp (TSS1500), or 200 bp
(TSS200) from the transcription start site, or in the 50UTR
region, or ﬁrst Exon; Fig. 1a). Hypermethylation of probes
located in the ﬁrst exon (Fig. 1b) is of particular interest as
hyper-methylation of the ﬁrst exon region silences gene
expression in a tighter fashion than TSS regions.21 Probes in
CpG islands were hypermethylated in PDAC compared with
nonmalignant pancreas (p-value < 0.0001; Fig. 1c). Probes in
shelf positions (2 kb from CpG islands) were hypomethy-
lated in PDAC samples (average beta-value 5 0.47 in PDAC
and 0.59 in nonmalignant pancreas; Fig. 1c); similar to the
pattern seen in colon cancer.6
Aberrant methylation discriminates PDAC and
nonmalignant pancreas independent of tumor cellularity
Hierarchical clustering using the robust set of DM probes (n
5 11,634) correctly classiﬁed 96% (134/140) of PDAC sam-
ples (Fig. 2). When 27 samples with <20% cellularity were
included in the analysis, PCA analyses and clustering con-
ﬁrmed that the robust DM CpG sites could correctly classify
samples 92% (153/167) of the time (Supporting Information
Figs. S5 and S6), although the degree of separation was inﬂu-
enced by tumor cellularity (Supporting Information Fig. S6).
These results suggest that aberrantly methylated sites have
potential applicability as biomarkers for PDAC.
In other cancers (colorectal and gastric), methylation pat-
terns can deﬁne clinically signiﬁcant subtypes.22,23 To assess
if DNA methylation could identify subtypes in PDAC, we
performed clustering analysis using RPMM with the top
2,786 most variable probes across all tumor samples. Four
clusters were identiﬁed (Supporting Information Fig. S7);
however, these subgroups did not cosegregate with patient
survival (Supporting Information Fig. S8), or other key clini-
cal features (age, gender or tumor grade; data not shown).
Aberrant methylation and mRNA expression identifies
candidate genes that are epigenetically regulated
The robust set of 11,634 DM CpG sites was mapped onto
genomic features associated with 5,668 RefSeq transcripts and
3,522 genes using array vendor’s annotations (Supporting
Information Table S4), 850 of these genes had been previ-
ously reported as DM in previous PDAC methylation stud-
ies11,13,24 (Supporting Information Table S5). In the samples
(n 5 129) with mRNA expression array data available, 33%
of aberrantly methylated genes also showed signiﬁcant
methylation-gene expression correlation (q-value < 0.05;
Supporting Information Tables S6 and S7). Approximately
86% of these genes showed inverse correlations between
methylation and gene expression (Supporting Information
Table S6) consistent with hypermethylation promoting gene
silencing and hypomethylation increasing expression. A set of
178 CpGs had positive correlation between methylation and
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Figure 1. Genomic distribution of DM probes (n 5 11,634) in CpG island and other parts of the genome. (a) Pie charts show the genomic
distribution of hypomethylated and hypermethylated probes across different genomic regions (Island 5 probes located at CpG islands,
Shore probes located less 2kb from CpG island, Shelf 5 probes located >2k from CpG islands, Open Sea 5 probes not in island or anno-
tated genes; TSS1500 and TSS200 – probes located within 1500 and 200 bp from transcription start site, respectively; 50UTR region; first
exon; gene body and 30UTR region). (b) Box plot of levels of methylation across gene regions for PDAC samples (n 5 140) and adjacent
nonmalignant samples (n 5 29). Whiskers represent max and min values. (c) Methylation levels across CpG island regions for PDAC sam-
ples and adjacent nonmalignant pancreatic samples. Whiskers represent max and min values (p-values were computed with Wilcoxon rank
sum test). The number of probes in each region are TSS1500 n 5 1,596, TSS200 n 5 1,443, 50UTR n 5 1,741, first exon n 5 1,282, Body
n 5 3,782, 30UTR n 5 257, Island 5 5,329, Shore 5 1,888, Shelf 5 658 and Open Sea 5 1,457.
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expression, the majority (n 5 128) of which were located in
gene bodies (Supporting Information Table S6).
Pathways affected by aberrant DNA methylation in PDAC
First, the entire set of genes (n 5 3,522) associated with the
robust DM probe set was used for pathway analysis. Ingenu-
ity pathway analysis revealed 25 pathways signiﬁcantly
affected by DNA methylation in PDACs (adjusted p-value <
0.001; Supporting Information Table S8). Axon guidance was
one of the most signiﬁcant (adjusted p-value 5 1.91E-05)
and was supported by MetaCore pathway analysis (FDR 5
1.21E-10; Supporting Information Table S9). This pathway
was recently implicated in PDAC.10 Other pathways identi-
ﬁed here as enriched for genes aberrantly methylated (Sup-
porting Information Tables S8 and S9) including cell
adhesion, hedgehog signaling, TGF-b, integrin signaling and
WNT/NOTCH signaling are well known key cancer signaling
previously describe to be genetically altered in PDAC.8 WNT
signaling has been reported to be aberrant methylated in
PDAC cell lines.13 Our results conﬁrm that this pathway is
aberrantly methylated in this large cohort of PDAC.
Stellate cell activation (adjusted p-value 5 3.26E-05) another
interesting pathway identiﬁed here as signiﬁcantly affected by
DNA methylation (Supporting Information Table S8)
deserves further investigation due its importance in PDAC.
Pancreatic stellate cells are the main ﬁbroblastic cells in
PDAC25 and are known to interact with pancreatic cancer
cells creating the ﬁbrotic microenvironment of PDAC.24 The
ﬁbrotic microenvironment of PDAC has been suggested to
create a barrier that impairs the delivery of chemotherapeu-
tics and promotes aggressive neoplastic cell behavior.25
Known genes known to be involved in stellate cell activation
(COX2, TGFBR1, EGFR, TNF and MET were hypo-
methylated in PDAC and conﬁrmed bisulﬁte amplicon deep
sequencing (Supporting Information Figs. S9–S14).
Ingenuity and MetaCore pathway analyses were also per-
formed using 1,158 genes with signiﬁcant correlation of
methylation with mRNA expression levels. A similar enrich-
ment for cell adhesion, apoptosis, invasion and cell prolifera-
tion processes was seen in meta-core analysis speciﬁcally, cell
adhesion: FDR 5 1.4E-08, WNT signaling: FDR 5 3.1E-07,
axon guidance: FDR 5 2.0E-05, EMT regulation: FDR 5
3.3E-05 and integrin mediated cell adhesion: FDR59.3E-03;
Supporting Information Table S10). IPA analysis provided
Figure 2. Cluster of PDAC (n 5 140) and adjacent nonmalignant samples (n 5 29) using 11,634 DM probes (adjusted p-value < 0.001 and
Db value  0.20). Columns are samples and rows are DM probes. Beta-value equal zero means site is completely unmethylated and one
completely methylated. CpG site locations are depicted on the left column of the graph (Black bars 5 probe located in CpG island, gray
bars 5 probe is in other location of the genome). Clinical information is plotted above the cluster and details presented in the legends.
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further supportive evidence for aberrant methylation of com-
ponents of axon guidance (adjusted p-value 5 9.53E-03) and
integrin signaling (adjusted p-value 5 4.38E-03; Supporting
Information Table S11).
Based on these data, and the recently reported high preva-
lence of mutations and copy number alterations of axon guid-
ance genes, particular those involved in SLIT-ROBO signaling
in PDAC10 we performed a detailed epigenetic and transcrip-
tomic review to determine whether somatic epigenetic events
are enriched in this pathway. Hyper-methylation of ROBO1,
ROBO3, SLIT3, SLIT2 and hypomethylation of ITAG2 and
MET (a known interacting partner of SRGAP1) were observed
in the methylation array data. Deep-amplicon sequencing of
bisulﬁte converted DNA for CpG sites in those genes validated
DM (Supporting Information Figs. S9 and S14–S19). Deep-
amplicon sequencing also showed that the regions surrounding
the CpG sites interrogated in the array have similar levels of
hypermethylation or hypomethylation (Supporting Information
Figs. S10 and S19) as expected due to the high degree of
locally correlated DNA methylation.26 Arrays and amplicon
sequencing results showed high concordance of the methyla-
tion levels (average Spearman correlation 5 0.88, Supporting
Information Fig. S9) validating array results and suggesting
epigenetic inactivation of SLIT-ROBO signaling pathway and
hypomethylation of MET and ITAG2 in PDAC.
Signiﬁcant inverse correlations between methylation and
array based mRNA expression were observed for SLIT2,
SLIT3, ITGA2 and MET genes (Supporting Information Fig.
S20) that were validated using qRT-PCR (Supporting Infor-
mation Fig. S21). Although array mRNA expression levels for
ROBO1 and ROBO3 were at the limit of detection and
showed no correlation with arrays (Supporting Information
Fig. S22), qRT-PCR analysis demonstrated signiﬁcant inverse
correlation for ROBO1, ROBO3 genes (p-value  0.05; Sup-
porting Information Fig. S21).
DM and altered mRNA expression of MET and ITGA2 is
associated with patient survival
Given that mRNA expression of ROBO2 and ROBO3 has
recently been associated with poor outcome of PDAC
patients10 and the observed wide spread altered methylation
and expression of SLIT-ROBO signaling and their interactive
partners, we sought to discern whether these events had any
clinical signiﬁcance. While SLIT2, SLIT3 and ITGB4 all
showed correlation of methylation and expression levels
(Supporting Information Tables S6 and S7), they did not cor-
relate with survival in this cohort (Supporting Information
Fig. S23). Interestingly, patients with coordinated hypomethy-
lation and high expression of MET and ITGA2 strongly cor-
related with poor outcome (p-value 5 0.007 and 0.04,
respectively; Fig. 3). While these genes are known to be
involved in hepatocyte growth factor (HGF)/MET and Integ-
rin signaling pathways, they both signal through CDC42, a
core signal transduction molecule, which is actively sup-
pressed by normal SLIT-ROBO signaling.
Discussion
This study reports the largest genome-wide scan of DNA
methylation in PDAC to date. The large sample size and rig-
orous statistical threshold led to the identiﬁcation of DM
CpG sites that robustly differentiate PDAC from nonmalig-
nant pancreas, even for samples with low cellularity. These
results suggest that DNA methylation may have potential
role in the diagnosis of PDAC, and supports further
exploration.
The majority of hypermethylated sites are located in CpG
islands and promoter regions as previously observed in other
cancer types.6,27 Genes affected by gene-body hypomethyla-
tion might be interesting targets for further studies as intra-
genic methylation is associated with regulation of intragenic
promoter activity and alternative transcription in a tissue and
Figure 3. Kaplan-Meier survival curves show cosegregation of gene expression of ITGA2 and MET with clinical outcome. Patients with high
mRNA expression of ITGA2 and MET genes showed lower survival. Median survival of patients presenting lower gene expression of ITGA2 is
21.4 months compared with 13.8 months for high ITAG2 expressing patients. Patients presenting lower level of MET expression have 25.6
months median survival compared with high expressing patients, which median survival is 15.9 months.
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cell speciﬁc manner.28 Of the 3,522 aberrantly methylated
genes in PDAC, 850 (Supporting Information Table S5) were
previously reported to be aberrantly methylated in pancreatic
cancer cell lines.11–13 This set constitutes almost half of the
DM genes identiﬁed by Vincent et al.13 where a 244,000 CpG
array screen was performed on 9 PDAC cell lines and 3
unmatched laser captured normal pancreatic duct samples.
These results suggest that the limitation of cellularity did not
seriously confound our study. Furthermore, the strong con-
cordance provides conﬁdence that while the normal tissue
control used in this study is not ideal, it is appropriate.
Finally is important to note that differences between these
two studies warrant further investigation as they may provide
insights about the role of DNA methylation in altering other
cell types present in the tumor microenvironment and DNA
methylation events driven by prolonged cell culture.
Core signaling pathways involved in cell adhesion, apoptosis,
invasion and cell proliferation were identiﬁed as recurrently
aberrantly methylated (Supporting Information Tables S7 and
S8). One interesting pathway signiﬁcantly altered by DNA
methylation in PDAC was the stellate cell activation (Supporting
Information Table S7). Pancreatic stellate cells are the main
ﬁbroblastic cells in PDAC29 and are known to interact with pan-
creatic cancer cells creating the ﬁbrotic microenvironment of
PDAC. Activated pancreatic stellate cells secrete extracellular
matrix proteins that stimulate cancer cell proliferation support-
ing tumor growth and metastatic spreading, inhibiting apoptosis
and enhancing angiogenesis.24,30 Stromal activation is promoted
by multiple cancer cell-derived signaling pathways such as TGF-
b, HGF/MET, FGFs, IGF-1 and EGF via autocrine and para-
crine mechanisms.25 Members of these pathways were aber-
rantly methylated in PDAC. COX2, TGFBR1, EGFR, TNF and
MET molecules known to be involved in stellate cell activation
were hypomethylated in PDAC and conﬁrmed by deep sequenc-
ing, suggesting that deregulated DNA methylation may inﬂu-
ence stellate activation in PDAC. This cross-talk between stellate
and cancer cells could be epigenetically regulated opening new
avenues for therapeutic development, as pancreatic stellate cells
have been shown to promote epithelial-mesenchymal transition
in pancreatic cancer cell lines31 and ﬁbrotic tissue has been sug-
gested to impact delivery of chemotherapeutics and promote
aggressive neoplastic cell behavior in PDAC.25
Recent data suggest a role for genes involved in axon guid-
ance pathway in tumorigenesis and tumor progression for a
variety of cancer types including PDAC10 and this pathway is
being explored as a potential biomarker and therapeutic target
in breast cancer.32 Our results suggest additional perturbation
of axon guidance through epigenetic inactivation of the SLIT-
ROBO signaling, a major component of axon guidance. SLIT-
ROBO signaling modulates HGF/MET and WNT signaling
activity, both known to play important roles in carcinogene-
sis.33 Dallol et al.34 identiﬁed hyper-methylation of the
ROBO1 gene in 19% of breast carcinomas and 18% of clear
cell renal cell carcinomas. Narayan et al.35 showed hyper-
methylation of SLIT1, SLIT2, SLIT3, ROBO1 and ROBO3
genes in cervical cancer, suggesting that the hypermethylation
of SLIT-ROBO signaling genes may be associated with cervi-
cal cancer progression. Interestingly, Vincent et al.13 identiﬁed
aberrant methylation of ROBO1, ROBO3, SLIT2 and SLIT3 in
pancreatic cell lines. In addition, inactivation of the SLIT-
ROBO pathway is associated with increased metastasis in mel-
anoma cells.36 Over-expression of SLIT2 signiﬁcantly
decreased invasion and migration in breast cancer cell lines
and mice injected with SLIT2 expressing cells have a reduc-
tion of breast carcinoma incidence of 60%.37
Biankin et al.10 identiﬁed genomic aberrations of ROBO1
in 11% (10% loss and 1% mutation) and SLIT2 in 10% (7%
loss and 3% mutation) of PDAC samples. Here for a subset
of 58 tumors that exome or whole genome sequencing data
was available (ICGC portal: http://dcc.icgc.org/) we identiﬁed
tumors with loss of one allele, non-silent mutation or hyper-
methylation in ROBO1, ROBO3, SLIT2 and SLIT3 genes.
Similar levels of loss and mutation rate previously reported10
were observed in this small cohort (Supporting Information
Fig. S24). A small proportion of the tumors presented muta-
tion or loss of one allele and hypermethylation; however, the
data presented here suggest that hypermethylation of SLIT-
ROBO is a more wide spread mechanism of inactivation of
this pathway. From the 58 tumors 48% showed hypermethyl-
ation of all four genes (ROBO1, ROBO3, SLIT2 and SLIT3;
Supporting Information Fig. S25). The hypermethylation of
these genes and signiﬁcant negative correlation with gene
expression suggests epigenetic inactivation of SLIT-ROBO
signaling in PDAC and constitutes an alternative mechanism
to disrupt this pathway. The importance of DNA methylation
cooperating with other genetic mechanisms to alter key sig-
naling pathways critical to cancer development is well estab-
lished.22,38 Hypermethylation has been shown to be a
preferred mechanism for inactivation of tumor suppressor in
other cancers,39 suggesting that tumor suppressor genes with
a low incidence of mutations can use epigenetic inactivation
more frequently.
Both MET and IGTA2 genes were hypomethylated in
PDAC and this correlated inversely with gene expression
using arrays (q-value 5 1.35E-08 and 4.10E-10, respectively)
and RT-PCR (Supporting Information Fig. S21). In addition,
high gene expression correlated with poor patient survival
(Fig. 3). MET encodes a tyrosine kinase receptor for the HGF
and is a poor prognostic indicator in other cancer types.40
MET promotes a broad range of promalignant processes
including cell motility, cell proliferation, invasion and metas-
tasis.40 The potential role of ITGA2 in tumorigenesis is less
well understood. ITGA2 gene encodes the alpha subunit of a
transmembrane receptor for collagen (ITGA2/ITGB1), which
is implicated in cell adhesion and migration.41 ITGA2 was
found previously to be upregulated in PDAC in a meta-
analysis of four independent studies.42 Finally, both MET and
ITGA2 signal via CDC42,43–45 the key effector molecule that
is normally suppressed by active SLIT-ROBO signaling. Epi-
genetic or other mechanisms of suppression of SLIT-ROBO
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signaling would amplify the effect of elevated expression of
MET and ITGA2.
In summary, this large cohort screen provides evidence that
aberrant DNA methylation and altered gene expression targets
key pathways important to PDAC tumorigenesis and provides
several candidate genes for future investigations. Taken
together these data suggest an orchestrated epigenetic deregu-
lation that plays a role in promoting pro-malignant cues that
contribute to the aggressive nature of pancreatic cancer.
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